Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 8:19 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Venous Thromboses Clear all
Not listed No phase listed Observational Accepts healthy volunteers

Doppler Ultrasound Imaging of Plastic Surgery Patients for DVT Detection

NCT02123550
View directory record Official record
Conditions
Deep Venous Thrombosis
Interventions
Not listed
Lead sponsor
Swanson Center
Other
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2022
U.S. locations
1
States / cities
Leawood, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 9, 2018 · Synced Jul 22, 2026, 8:19 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Intravitreal Ranibizumab 0.5MG, or 1.0mg for RVO With Macular Edema Previously Receiving Bevacizumab

NCT01471691
View directory record Official record
Conditions
Branch Retinal Vein Occlusion, Central Retinal Vein Occlusion, Macular Edema
Interventions
ranibizumab 0.5mg, ranibizumab 1.0mg
Drug
Lead sponsor
Hanscom, Thomas, M.D.
Individual
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
4
States / cities
Huntington Beach, California • Long Beach, California • Santa Monica, California + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2015 · Synced Jul 22, 2026, 8:19 PM EDT
Completed Not applicable Interventional

A Universal Electronic Health Record-based IMPROVE DD VTE Risk Assessment Model for the Prevention of Thromboembolism in Hospitalized Medically Ill Patients

NCT04768036
View directory record Official record
Conditions
Venous Thromboembolism, Arterial Thromboembolism
Interventions
IMPROVE DD VTE Tool
Other
Lead sponsor
Northwell Health
Other
Eligibility
60 Years and older
Enrollment
10,699 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
5
States / cities
Manhasset, New York • New Hyde Park, New York • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2022 · Synced Jul 22, 2026, 8:19 PM EDT
Completed Early Phase 1 Interventional

Ultrasound Elasticity Imaging of Venous Thrombi

NCT00726947
View directory record Official record
Conditions
Thrombosis
Interventions
Ultrasound
Procedure
Lead sponsor
University of Michigan
Other
Eligibility
Not listed
Enrollment
254 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2011
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated May 23, 2016 · Synced Jul 22, 2026, 8:19 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Patient Safety Learning Laboratory: Making Acute Care More Patient-Centered

NCT02969343
View directory record Official record
Conditions
Central Line-Associated Bloodstream Infection (CLABSI), Venous Thromboembolism, Patient Fall, Catheter-Associated Infection, Severe Hypoglycemia, Opioid-Related Severe Adverse Drug Event, Hospital Acquired Pressure Ulcer, Adverse Drug Event, Severe Hospital Acquired Delerium, Rapid Response Related to Arrhythmia
Interventions
Patient Safety health information technology
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 99 Years
Enrollment
21,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 9, 2019 · Synced Jul 22, 2026, 8:19 PM EDT
Completed No phase listed Observational

Multi-Center Human Alert Trial to Prevent DVT and PE

NCT00409136
View directory record Official record
Conditions
Pulmonary Embolism, Deep Vein Thrombosis, Cancer, Surgery
Interventions
Human Alert
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
2,496 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
26
States / cities
Scottsdale, Arizona • Long Beach, California • Orange, California + 22 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2009 · Synced Jul 22, 2026, 8:19 PM EDT
Terminated Phase 3 Interventional Results available

Efficacy Evaluation of TheraSphere to Treat Inoperable Liver Cancer With Blockage of the Portal Vein

NCT01887717
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
TheraSphere®, Sorafenib
Device · Drug
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
2
States / cities
Chicago, Illinois • New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 20, 2021 · Synced Jul 22, 2026, 8:19 PM EDT
Completed Not applicable Interventional Results available

Pilot Study for VeinoPlus to Improve Symptoms of Postthrombotic Syndrome (PTS)

NCT00858130
View directory record Official record
Conditions
Post Thrombotic Syndrome, Deep Vein Thrombosis, Venous Stasis Syndrome, Venous Insufficiency, Postphlebitic Syndrome
Interventions
VeinOPlus
Device
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 28, 2017 · Synced Jul 22, 2026, 8:19 PM EDT
Not listed No phase listed Observational

Cancer Patients Diagnosed With Unsuspected Venous Thromboembolism (VTE) on Routine Computed Tomography (CT) Scans

NCT00925808
View directory record Official record
Conditions
Cancer, Venous Thromboembolism
Interventions
Questionnaires
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
1,187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 29, 2019 · Synced Jul 22, 2026, 8:19 PM EDT
Recruiting Not applicable Interventional

Intervention to Improve Utilization of Extended Venous Thromboembolism Prophylaxis After Cancer Surgery

NCT06451003
View directory record Official record
Conditions
Venous Thromboembolism, Pulmonary Embolism, Deep Vein Thrombosis, Cancer, Surgery
Interventions
Exposure to clinical decision support system and education
Behavioral
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jul 30, 2025 · Synced Jul 22, 2026, 8:19 PM EDT
Completed Phase 2 Interventional Results available

Multiple Dose Safety and Efficacy of LKA651 in Patients With Diabetic Macular Edema

NCT03927690
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
LKA651, Lucentis
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
7
States / cities
Beverly Hills, California • Rancho Cordova, California • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 19, 2024 · Synced Jul 22, 2026, 8:19 PM EDT
Completed Phase 4 Interventional Results available

Extended-Duration Low-Intensity Apixaban to Prevent Recurrence in High-Risk Patients With Provoked Venous Thromboembolism

NCT04168203
View directory record Official record
Conditions
Deep Vein Thrombosis, Pulmonary Embolism, Venous Thromboembolism
Interventions
Apixaban 2.5 MG, Placebo oral tablet
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 13, 2025 · Synced Jul 22, 2026, 8:19 PM EDT
Completed No phase listed Observational

Risk of Central Venous Stenosis in Patients With Chronic Renal Failure After IJ Line Placement

NCT01988766
View directory record Official record
Conditions
Thrombosis
Interventions
Not listed
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
1,424 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 23, 2014 · Synced Jul 22, 2026, 8:19 PM EDT
Withdrawn Phase 4 Interventional

Is Using Fondaparinux (Blood Thinner) to Treat Lung Clot Cheaper Than Traditional Therapy

NCT00377091
View directory record Official record
Conditions
Pulmonary Embolism
Interventions
Fondaparinux
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
1
States / cities
Duluth, Minnesota
Source: ClinicalTrials.gov public record
Updated May 29, 2013 · Synced Jul 22, 2026, 8:19 PM EDT
Completed No phase listed Observational

Biomarker Sub Study of the Compression Stockings to Prevent the Post-Thrombotic Syndrome (SOX) Trial

NCT01615705
View directory record Official record
Conditions
Deep Venous Thrombosis
Interventions
Not listed
Lead sponsor
Sir Mortimer B. Davis - Jewish General Hospital
Other
Eligibility
18 Years and older
Enrollment
803 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
3
States / cities
Detroit, Michigan • Durham, North Carolina • Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jun 10, 2012 · Synced Jul 22, 2026, 8:19 PM EDT
Completed Not applicable Interventional Results available

Post-thrombotic Syndrome & Predictors of Recurrence in Catheter-related Thrombosis

NCT01999179
View directory record Official record
Conditions
Venous Thrombosis, Neoplasms
Interventions
Heparin, Low-Molecular-Weight, or direct oral anticoagulants
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
3
States / cities
Minneapolis, Minnesota • Columbus, Ohio • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 17, 2022 · Synced Jul 22, 2026, 8:19 PM EDT
Completed Phase 2 Interventional

Pegaptanib Sodium Compared to Sham Injection in Patients With Recent Vision Loss Due to Macular Edema Secondary to Central Retinal Vein Occlusion (CRVO)

NCT00088283
View directory record Official record
Conditions
Retinal Vein Occlusion
Interventions
pegaptanib sodium
Drug
Lead sponsor
Eyetech Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
35
States / cities
Tucson, Arizona • Los Angeles, California • Santa Ana, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2007 · Synced Jul 22, 2026, 8:19 PM EDT
Terminated Phase 1 Interventional

Safety and Efficacy of Tissue Plasminogen Activator (tPA) in Neonates and Infants

NCT00265005
View directory record Official record
Conditions
Thrombosis
Interventions
alteplase
Drug
Lead sponsor
University of Louisville
Other
Eligibility
28 Weeks to 66 Weeks
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Apr 3, 2018 · Synced Jul 22, 2026, 8:19 PM EDT
Completed No phase listed Observational

Microsurgical Breast Reconstruction & VTE

NCT03031457
View directory record Official record
Conditions
Breast Reconstruction, Venous Thromboembolism
Interventions
Duplex ultrasound
Diagnostic Test
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 90 Years · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Apr 30, 2018 · Synced Jul 22, 2026, 8:19 PM EDT
Completed Phase 3 Interventional Results available

Study Investigating the Safety and Efficacy of HP802-247 in the Treatment of Venous Leg Ulcers >12 cm2 to ≤ 36 cm2

NCT01737762
View directory record Official record
Conditions
Venous Leg Ulcers
Interventions
HP802-247, Vehicle
Biological
Lead sponsor
Healthpoint
Industry
Eligibility
18 Years and older
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
37
States / cities
Phoenix, Arizona • Carlsbad, California • Castro Valley, California + 32 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2017 · Synced Jul 22, 2026, 8:19 PM EDT
Completed Not applicable Interventional

The RETRIEVE Study: Use of the FiberNet® Embolic Protection System in Saphenous Vein Grafts

NCT00453518
View directory record Official record
Conditions
Saphenous Vein Graft Disease, Myocardial Ischemia, Embolism
Interventions
FiberNet EPS used during SVG intervention.
Device
Lead sponsor
Lumen Biomedical
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
6
States / cities
Ocala, Florida • Indianapolis, Indiana • Royal Oak, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2009 · Synced Jul 22, 2026, 8:19 PM EDT
Completed No phase listed Observational

Replication of the EINSTEIN-DVT Anticoagulant Trial in Healthcare Claims Data

NCT04736420
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Rivaroxaban, Warfarin
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
78,605 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Jul 22, 2026, 8:19 PM EDT
Completed Phase 2 Interventional

Posterior Vitreous Detachment (PVD) Assessment During Dual Retinal Vein Occlusion (RVO) Lucentis Evaluations

NCT00831350
View directory record Official record
Conditions
Retinal Vein Occlusion, Posterior Vitreous Detachment
Interventions
Ranibizumab
Drug
Lead sponsor
Barnes Retina Institute
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 29, 2017 · Synced Jul 22, 2026, 8:19 PM EDT
Not listed No phase listed Observational

The DARE Warfarin CER Study

NCT03271450
View directory record Official record
Conditions
Deep Venous Thrombosis, Pulmonary Embolism
Interventions
Dabigatran: extended treatment (e.g at least 90 days), Dabigatran: extended treatment (e.g at least 180 days), Dabigatran: extended treatment (e.g at least 270 days), Apixaban: extended treatment (e.g at least 90 days), Apixaban: extended treatment (e.g at least 180 days), Apixaban: extended treatment (e.g at least 270 days), Rivaroxaban: extended treatment (e.g at least 90 days), Rivaroxaban: extended treatment (e.g at least 180 days), Rivaroxaban: extended treatment (e.g at least 270 days), Edoxaban: extended treatment (e.g at least 90 days), Edoxaban: extended treatment (e.g at least 180 days), Edoxaban: extended treatment (e.g at least 270 days), Warfarin: extended treatment (e.g at least 90 days), Warfarin: extended treatment (e.g at least 180 days), Warfarin: extended treatment (e.g at least 270 days)
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
416,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 22, 2021 · Synced Jul 22, 2026, 8:19 PM EDT